Singapore SingaporeSG China ChinaCN Malaysia MalaysiaMY Indonesia IndonesiaID Myanmar MyanmarMM Registration Log In
    • Products
      • General Laboratory
      • Life Science
      • Bio Reagents & Consumables
      • Analytical Science
      • Material Science & Nanotechnology
      • Pharmaceuticals
      • Medical
      • Safety Equipment
      • Customization Products & Turnkey Projects
    • Brands
    • Services
      • Exclusive Services
      • Customization and Fabrication
      • Environmental Monitoring Solutions - Data Loggers/ Alarms
      • Equipment Shifting/ Re-location
      • Product Sourcing
    • Contact Us
    • Home
    • About Us
    • Careers
    • Promotions
    • News & Events
    • Webinars
    • Our Network
    +65 6897 2772 / +65 6270 8884 / enquiry@gaiascience.com.sg Cart: 0

    Bio Reagents & Consumables

    1. Home
    2. Products
    3. Bio Reagents & Consumables
    4. Transfection Reagents
    5. Lipofection
    6. HeLaFect Transfection Reagent
    Back

    Lipofection

    HeLaFect Transfection Reagent

    HeLaFect Transfection Reagent

    For HeLa cell transfection
    Pricing & Availability Download Catalogue Add to wishlist OZ Biosciences
    Brand: OZ Biosciences Available Quick Share:
    Add to Cart Contact Us for better pricing. Warranty Details
    Free delivery within Singapore only
    • Overview
    • Specification
    • Downloads
    • Publications
    • Product Images
    • Product Videos
    • Product Enquiry

    Overview

    HeLaFect is a transfection reagent specifically developed for HeLa cell lineage transfection with high efficiency. HeLaFect is a lipid-based reagent based on the Tee-Technology (“Triggered Endosomal Escape”). The cationic design of HeLaFect reagent allows high nucleic acid compaction for an efficient transport into HeLa cells. This reagent is composed of biodegradable lipids leading to high viability and is ready-to-use.

    HeLaFect transfection reagent benefits:

    • Highly efficient: more than 80% of transfected HeLa cells
    • Ready-to-use: no need for additional buffer
    • Low nucleic acid amount - minimized toxicity
    • High level of nucleic acid compaction
    • Easy and straightforward protocol
    • Compatible with any culture medium: medium change not required

    Sizes:

    • 500µL: 125-250 transfections with 1µg of DNA

    • 1mL: 250-500 transfections with 1µg of DNA

    • 5mL: 1250-2500 transfections with 1µg of DNA

    Storage: -20°C

    Shipping Conditions: Room Temperature

    CATALOG NUMBER UNIT SIZE
    HF20500

    500 µL

    HF21000

    1 mL

    HF25000

    5 mL

     

    Applications

     RECOMMENDED APPLICATIONS: Nucleic acids transfection into HeLa cells.

     

    Results

    HeLaFect Transfection Reagent results

    Figure1: Complexes of DNA and HeLaFect were prepared with 0.5 μg per well in a 24-well plate at a 2:1 ratio, and DNA transfections with other commercial transfection reagents were performed as recommended by the manufacturers. 24 h after, transfection efficiency was measured by FACS analysis and fluorescence microscopy.

    Specification :
    Technical Resources Kindly refer to the "Downloads" tab.
    HeLaFect_OZ_Biosciences_transfection_reagent_Protocol1.pdf
    HeLaFect_Protocol_OZBiosciences1.pdf
    HeLaFect_OZ_Biosciences_Results.pdf
    MSDS_HeLaFect.pdf
    HeLaFect Transfection Reagent HeLaFect Transfection Reagent HeLaFect Transfection Reagent HeLaFect Transfection Reagent
    Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry

    Heikkinen T., Hum Mutat. 2017 Jan 5.

    MED12 is a key component of the transcription-regulating Mediator complex. Specific missense and in-frame insertion/deletion mutations in exons 1 and 2 have been identified in uterine leiomyomas, breast tumors, and chronic lymphocytic leukemia. Here, we characterize the first MED12 5' end nonsense mutation (c.97G>T, p.E33X) identified in acute lymphoblastic leukemia and show that it escapes nonsense-mediated mRNA decay (NMD) by using an alternative translation initiation site. The resulting N-terminally truncated protein is unable to enter the nucleus due to the lack of identified nuclear localization signal (NLS). The absence of NLS prevents the mutant MED12 protein to be recognized by importin-α and subsequent loading into the nuclear pore complex. Due to this mislocalization, all interactions between the MED12 mutant and other Mediator components are lost. Our findings provide new mechanistic insights into the MED12 functions and indicate that somatic nonsense mutations in early exons may avoid NMD.

    The prefoldin complex stabilizes the von Hippel-Lindau protein against aggregation and degradation

    Chesnel F., Plos Genet. 2020 Nov 2;16(11):e1009183.

    Loss of von Hippel-Lindau protein pVHL function promotes VHL diseases, including sporadic and inherited clear cell Renal Cell Carcinoma (ccRCC). Mechanisms controlling pVHL function and regulation, including folding and stability, remain elusive. Here, we have identified the conserved cochaperone prefoldin complex in a screen for pVHL interactors. The prefoldin complex delivers non-native proteins to the chaperonin T-complex-protein-1-ring (TRiC) or Cytosolic Chaperonin containing TCP-1 (CCT) to assist folding of newly synthesized polypeptides. The pVHL-prefoldin interaction was confirmed in human cells and prefoldin knock-down reduced pVHL expression levels. Furthermore, when pVHL was expressed in Schizosaccharomyces pombe, all prefoldin mutants promoted its aggregation. We mapped the interaction of prefoldin with pVHL at the exon2-exon3 junction encoded region. Low levels of the PFDN3 prefoldin subunit were associated with poor survival in ccRCC patients harboring VHL mutations. Our results link the prefoldin complex with pVHL folding and this may impact VHL diseases progression.

    Increased KCNJ18 promoter activity as a mechanism in atypical normokalemic periodic paralysis

    Soufi M., Neurol Genet. 2018 Oct 3;4(5):e274.

    lthough we did not identify harmful mutations in SCN4A, CACNA1S, KCNJ2 and KCNE3, we detected a monoallelic four-fold variant in KCNJ18 (R39Q/R40H/A56E/I249V), together with a variant in the respective promoter of this channel (c.-542T/A). The exonic variants in Kir2.6 did not alter the channel function; however, luciferase assays revealed a 10-fold higher promoter activity of the c.-542A promoter construct, which is likely to cause a gain-of-function by increased expression of Kir2.6. We found that reducing extracellular K+ levels causes a paradoxical reduction in outward currents, similar to that described for other inward rectifying K+ channels. Thus, reducing the extracellular K+ levels might be a therapeutic strategy to antagonize the transcriptionally increased KCNJ18 currents. Consistently, treatment of the patient with K+ reducing drugs dramatically improved the health situation and prevented PP attacks.

    Efficient C•G-to-G•C base editors developed using CRISPRi screens, target-library analysis, and machine learning

    Koblan LW., Nat Biotechnol . 2021 Jun 28. doi: 10.1038/s41587-021-00938-z.

    Programmable C•G-to-G•C base editors (CGBEs) have broad scientific and therapeutic potential, but their editing outcomes have proved difficult to predict and their editing efficiency and product purity are often low. We describe a suite of engineered CGBEs paired with machine learning models to enable efficient, high-purity C•G-to-G•C base editing. We performed a CRISPR interference (CRISPRi) screen targeting DNA repair genes to identify factors that affect C•G-to-G•C editing outcomes and used these insights to develop CGBEs with diverse editing profiles. We characterized ten promising CGBEs on a library of 10,638 genomically integrated target sites in mammalian cells and trained machine learning models that accurately predict the purity and yield of editing outcomes (R = 0.90) using these data. These CGBEs enable correction to the wild-type coding sequence of 546 disease-related transversion single-nucleotide variants (SNVs) with >90% precision (mean 96%) and up to 70% efficiency (mean 14%). Computational prediction of optimal CGBE-single-guide RNA pairs enables high-purity transversion base editing at over fourfold more target sites than achieved using any single CGBE variant.

    Analysis and minimization of cellular RNA editing by DNA adenine base editors

    Rees HA., Sci Adv. 2019 May 8;5(5):eaax5717.

    Adenine base editors (ABEs) enable precise and efficient conversion of target A•T base pairs to G•C base pairs in genomic DNA with a minimum of by-products. While ABEs have been reported to exhibit minimal off-target DNA editing, off-target editing of cellular RNA by ABEs has not been examined in depth. Here, we demonstrate that a current ABE generates low but detectable levels of widespread adenosine-to-inosine editing in cellular RNAs. Using structure-guided principles to design mutations in both deaminase domains, we developed new ABE variants that retain their ability to edit DNA efficiently but show greatly reduced RNA editing activity, as well as lower off-target DNA editing activity and reduced indel by-product formation, in three mammalian cell lines. By decoupling DNA and RNA editing activities, these ABE variants increase the precision of adenine base editing by minimizing both RNA and DNA off-target editing activity.

    HeLaFect Transfection Reagent HeLaFect Transfection Reagent HeLaFect Transfection Reagent HeLaFect Transfection Reagent
    Videos coming soon...

     
    Back to product list
    • Previous Product
    • Next Product

    Warranty Details

    Email


     

    Keep in touch:

    Quick Links

    • Home
    • Products
    • About Us
    • Brands
    • Careers
    • Services
    • Contact Us
    • Promotions
    • News & Events
    • Webinars
    • Our Network

    Products

    • General Laboratory
    • Life Science
    • Bio Reagents & Consumables
    • Analytical Science
    • Material Science & Nanotechnology
    • Pharmaceuticals
    • Medical
    • Safety Equipment
    • Customization Products & Turnkey Projects

    Customer Service

    • Enquiry
    • Help & FAQ
    • Terms and Conditions

    Gaia Science Pte Ltd

    Block 102 E Pasir Panjang Road
    #02-07, Singapore-118529
    +65 6897 2772 +65 6270 8884 enquiry@gaiascience.com.sg
    Copyright © 2025 Gaia Science Pte. Ltd. All Rights Reserved.
    Powered By Xsosys

    Sign In Here

    Sign In to Start Your Session

    I Forgot My Password

    Main Menu

    Products

    • General Laboratory
    • Life Science
    • Bio Reagents & Consumables
    • Analytical Science
    • Material Science & Nanotechnology
    • Pharmaceuticals
    • Medical
    • Safety Equipment
    • Customization Products & Turnkey Projects

    Quick Links

    • Home
    • Products
    • About Us
    • Brands
    • Careers
    • Services
    • Contact Us
    • Promotions
    • News & Events
    • Webinars
    • Our Network

    Customer Service

    • Enquiry
    • Help & FAQ
    • Terms and Conditions